Not Signed In -
Abarelix |
Plenaxis |
Article: Abarelix
| Image:Abarelix.png | |
| Abarelix | |
| Systematic (IUPAC) name | |
| acetyl-D-ß-naphthylalanyl- D-4-chlorophenylalanyl-D-3-pyridylalanyl-L-seryl-L- N-methyl- tyrosyl-D-asparagyl-L-leucyl-L-N(e )-isopropyl-lysyl-L-prolyl-D-alanyl-amide | |
| Identifiers | |
| CAS number | 183552-38-7 |
| ATC code | L02BX01 |
| PubChem | ? |
| DrugBank | BTD00051 |
| Chemical data | |
| Formula | C72H95O14N14Cl |
| Mol. weight | 1416.06 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | 96-99% |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. | ? |
| Legal status | |
| Routes | ? |
Abarelix also called plenaxis is a drug used to reduce the amount of testosterone made in patients with advanced symptomatic prostate cancer for which no other treatment options are available. It belongs to the family of drugs called Gonadotropin-releasing hormone antagonists.
 | This medical treatment article is a stub. You can help Wikipedia by expanding it. |
Category: Medical treatment stubs
email this page
print this page
bookmark this page
feedback on this page
